Work

Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862)

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.5132

Authors: M. Hussain, R. Dunn, D. Rathkopf, W. Stadler, G. Wilding, D. C. Smith, D. Bradley, K. A. Cooney, J. Zweibel, H. Scher

Institutions: Memorial Sloan Kettering Cancer Center, University of Wisconsin–Madison, University of Michigan, University of Chicago, National Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602657206

Cites:

Cited by: 11

Related to: 10